Boundless Bio (BOLD) announced updates to its executive leadership team. Klaus Wagner, chief medical officer, or CMO, and Neil Abdollahian, chief business officer, or CBO, will depart the company at the end of December and in early January, respectively. James Freddo, current advisor to Boundless with nearly 30 years of clinical leadership experience in biopharmaceutical companies, will serve as interim CMO while the company conducts a search for a permanent hire. Boundless does not intend to appoint a new CBO at this time.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks